Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $50.67 Consensus PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $54.50.

Several analysts recently issued reports on ORKA shares. UBS Group initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Wedbush lifted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. HC Wainwright dropped their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Finally, Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 price objective for the company.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total transaction of $222,670.00. Following the transaction, the insider directly owned 1,518 shares in the company, valued at approximately $48,287.58. This trade represents a 82.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics during the third quarter valued at about $51,280,000. Avoro Capital Advisors LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. Deep Track Capital LP boosted its stake in shares of Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after buying an additional 735,983 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after acquiring an additional 676,865 shares in the last quarter. Finally, Synergy Asset Management LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $13,911,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $33.05 on Friday. Oruka Therapeutics has a one year low of $5.49 and a one year high of $36.51. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -17.39 and a beta of -0.38. The business has a 50-day simple moving average of $31.26 and a 200 day simple moving average of $24.16.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01. On average, sell-side analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.